A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours

Abstract Background We previously reported that low-dose, short-course sunitinib prior to neoadjuvant doxorubicin-cyclophosphamide (AC) normalised tumour vasculature and improved perfusion, but resulted in neutropenia and delayed subsequent cycles in breast cancer patients. This study combined sunit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Yvonne L. E. Ang, Gwo Fuang Ho, Ross A. Soo, Raghav Sundar, Sing Huang Tan, Wei Peng Yong, Samuel G. W. Ow, Joline S. J. Lim, Wan Qin Chong, Phyu Pyar Soe, Bee Choo Tai, Lingzhi Wang, Boon Cher Goh, Soo-Chin Lee
Format: Artigo
Idioma:Inglês
Publicat: BMC 2020-11-01
Col·lecció:BMC Cancer
Matèries:
Tumour vasculature
Anti-angiogenic
Short-course sunitinib
Advanced solid tumours
Docetaxel
Accés en línia:http://link.springer.com/article/10.1186/s12885-020-07616-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars